Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric single-arm study of iptacopan in primary IgA nephropathy
MOH_2025-09-28_014361Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2025-09-28_014361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-28_014361.